There are many different immunotherapeutic drugs approved by the Food and Drug Administration (FDA) to be used in cancer therapy: recombinant-human-IL-2 for renal cancer cell therapy; first monoclonal antibody for B-cell malignancies; first DC-based cancer vaccine for prostate cancer therapy; chimeric antigen receptor (CAR)-engineered cell therapy for B-cell lymphoma; and programmed death ligand-1 (PD-L1) immune checkpoint blockers for melanoma are examples of immunotherapeutics approved for use in the treatment of cancer in the last thirty years [27]. This evidence concerns the gene IL2 and cancer.